Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by chemotherapy followed by allo-SCT in eligible patients. However, following a flurry of drug approvals in 2017 and 2018, the AML treatment landscape is undergoing a transformation. The entry of novel agents into the treatment paradigm will enable the increasingly personalized treatment of patients, based on the characteristics of their disease and specific biomarkers. However, several areas of unmet need remain. Notably, patients unfit for intensive chemotherapy induction and relapsed/refractory AMLpatients offer significant commercial opportunity for innovative agents.
Label expansions and new drug approvals (e.g., FLT3 inhibitors, apoptosis-inducing agents) will fuel substantial growth of the AML therapy market over the 2017-2027 forecast period. This report provides insight on how treatment options for AML are likely to change over the 2017-2027 forecast period. It also analyzes the current and future earnings potential of AML therapies.
- What are the key drivers of growth over this period? What will be the major constraints on therapy sales? What are the drug development activities of note? What challenges and opportunities remain?
- What is thought-leader opinion of emerging therapies and drug classes? For which patient populations will these agents be positioned? Will second-generation FLT3inhibitors receive approval in the markets under study? How will use of these agents affect prescribing of other agents for AML?
- How do key opinion leaders view the use of emerging therapies in the maintenance setting? Will maintenance therapy become a part of standard AML treatment in the future?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 17 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incident cases of de novo AML and AML with MDS-related changes.
Population segments in market forecast: First-line AML, younger patients (aged < 60); first-line AML, older patients (aged ≥ 60); second-line AML, younger patients (aged < 60); second-line AML, older patients (aged ≥ 60); third-line AML.
Emerging therapies: Phase III: 11 drugs; Phase II: 27 drugs.